The Cellular Health Benefits of SS-31 Peptide

SS-31 is a small synthetic peptide that concentrates inside mitochondria and shields them from the kind of damage that accumulates with age, injury, and disease. Also known by its clinical name elamipretide, the peptide works by binding to cardiolipin, a fat molecule found only on the inner mitochondrial membrane, and this single interaction sets off a cascade of protective effects: less oxidative stress, more efficient energy production, and better-preserved cellular structures. Research spanning heart, brain, kidney, muscle, liver, and eye tissue has shown that these mitochondrial improvements translate into measurable functional gains in animal models, and human clinical trials in rare mitochondrial diseases have begun to show real-world benefits.

How SS-31 Works Inside Mitochondria

Mitochondria generate the energy your cells run on, but as a byproduct they also produce reactive oxygen species, the unstable molecules often called free radicals. When mitochondria are damaged or aging, free radical production rises while energy output drops. SS-31 targets this problem at its source by crossing the outer mitochondrial membrane and binding with high affinity to cardiolipin, a phospholipid that sits on the inner membrane and is essential for maintaining the folds (called cristae) where the energy-producing machinery is organized.¹

Cardiolipin does not just provide structural scaffolding. It also helps arrange the respiratory complexes, the protein assemblies that pass electrons along a chain to make ATP, into tightly packed supercomplexes. When cardiolipin is oxidized by free radicals, those supercomplexes fall apart, electron transfer becomes sloppy, more free radicals leak out, and even more cardiolipin gets damaged. SS-31 interrupts this vicious cycle. By interacting with cardiolipin, it prevents a key protein called cytochrome c from flipping into a destructive peroxidase mode while preserving its normal electron-carrying function.² The result is that cristae stay intact, energy production stays efficient, and the cascade of oxidative damage is dialed back.

One feature that separates SS-31 from a generic antioxidant is selectivity. The peptide appears to have no measurable effect on mitochondria that are already functioning normally. It reduces reactive oxygen species production and prevents mitochondrial swelling in damaged or stressed cells without disrupting healthy ones.³ That kind of conditional activity is important because mitochondrial signaling through low levels of reactive oxygen species is a normal and necessary part of cell biology. A blunt antioxidant that wiped out all mitochondrial reactive oxygen species could do more harm than good.

Reversing Age-Related Decline in Heart Function

The heart is one of the most mitochondria-dense organs in the body, and aging hearts show a predictable pattern of rising oxidative stress and declining efficiency. In aged mice, SS-31 treatment reduced both superoxide and hydrogen peroxide production inside heart muscle cells. It also normalized proton leak, a process where energy that should be captured as ATP instead dissipates as heat. This proton leak increases significantly with age, and SS-31 brought it back toward youthful levels.⁴

In a separate study using a mouse model of pressure-overload heart failure, SS-31 improved cardiac function and reduced the scarring (fibrosis) that stiffens the heart and worsens pumping ability. The mechanism depended on a protein called Sirt3 and its role in mitochondrial fusion, the process by which damaged mitochondria merge with healthier ones to maintain quality. When researchers knocked out Sirt3, SS-31’s benefits disappeared, suggesting the peptide does not simply mop up free radicals but works through specific signaling pathways that govern how mitochondria maintain themselves.⁵

Muscle Performance and Exercise Tolerance in Aging

Age-related muscle loss and weakness are closely tied to declining mitochondrial function in skeletal muscle. SS-31 has been tested in aged mice across multiple studies, and the results are strikingly consistent. Just one hour after a single treatment, aged skeletal muscle showed greater resistance to fatigue during direct electrical stimulation. After eight days of treatment, whole-body endurance capacity on a treadmill had measurably increased.⁶

Extending treatment to eight weeks produced even more dramatic results. Treadmill endurance roughly doubled compared to untreated aged animals. Critically, SS-31-treated aged mice actually improved their running performance by about 30% from their own pre-treatment baseline, while untreated aged mice declined by about 20% over the same period. The peptide was not merely slowing decline; it was reversing it. Young mice showed no change either way, reinforcing the idea that SS-31 specifically addresses age-related mitochondrial dysfunction rather than acting as a general performance enhancer.⁷

Part of this improvement traces to a specific transport bottleneck. With age, mitochondria become less responsive to ADP, the molecule that signals “make more ATP.” SS-31 treatment increased ADP uptake through a transporter on the inner mitochondrial membrane, effectively restoring the sensitivity of old mitochondria to energy demands. The same treatment rescued both muscle force and heart pumping function in aged animals.⁸

Kidney Protection Under Stress

Kidney tissue is metabolically expensive to maintain and highly vulnerable to mitochondrial dysfunction. In animal models of both acute injury and chronic disease, SS-31 has shown protective effects. During kidney ischemia, where blood flow is temporarily cut off and then restored, pre-treatment with SS-31 preserved cristae structure and prevented the mitochondrial swelling that typically follows reperfusion injury.¹

In a mouse model of diabetic kidney disease, SS-31 reduced the enlargement of tubular cells, attenuated tissue damage, and lowered expression of TGF-β1, a key driver of fibrosis.⁹ These findings matter because kidney fibrosis is the common endpoint of many chronic kidney diseases, and once established it is essentially irreversible with current treatments. An intervention that could slow or prevent mitochondrial-driven fibrosis would address one of the disease’s most stubborn features.

Brain Injury and Neuroinflammation

The brain consumes a disproportionate share of the body’s oxygen and is especially sensitive to mitochondrial failure. Two lines of animal research suggest SS-31 may offer neuroprotection under different forms of stress. In mice exposed to a bacterial toxin that triggers widespread inflammation, SS-31 treatment improved mitochondrial function in the brain and attenuated the memory impairment that normally follows systemic inflammation. The researchers concluded that the peptide had potential for preventing the kind of oxidative and inflammatory damage linked to cognitive problems after surgery or critical illness.¹⁰

A more recent study examined brain injury after cardiac arrest, a setting where the brain is starved of oxygen and then flooded with it once circulation returns. SS-31 improved survival rates, reduced markers of brain damage in the blood, and shifted the brain’s immune cells away from a destructive inflammatory state. The mechanism involved reducing a form of cell death called ferroptosis, in which iron accumulation drives lethal lipid oxidation within cells.¹¹

Metabolic and Liver Health

Diabetes causes widespread mitochondrial dysfunction, and SS-31 has been tested in diabetic animal models with encouraging results. In a genetic mouse model of type 2 diabetes, treatment with SS-31 reversed most of the mitochondrial deficits, restoring both mitochondrial function and the dynamic processes by which mitochondria divide and fuse to maintain quality control.¹²

Liver disease associated with metabolic dysfunction (sometimes called MASLD, the condition formerly known as non-alcoholic fatty liver disease) is another area where mitochondrial damage plays a central role. In aged female mice fed a high-fat diet, SS-31 improved mitochondrial protein levels and overall liver health. It also improved insulin sensitivity by boosting the signaling that helps cells take up glucose. A direct comparison with MitoQ, another mitochondria-targeted compound, found that while both improved outcomes, SS-31 was more effective at preserving mitochondrial structural integrity, while MitoQ had a stronger effect on boosting antioxidant defenses. Both reduced fibrosis.¹³ That kind of head-to-head comparison is rare in this field and suggests that different mitochondria-targeted therapies may have complementary mechanisms worth exploring.

Protecting the Retina

The retinal pigment epithelium (RPE), a single layer of cells behind the retina, does an enormous amount of metabolic work to support the photoreceptors that let you see. When RPE cells are damaged by oxidative stress, the resulting dysfunction contributes to conditions like age-related macular degeneration. In cell culture models, SS-31 protected RPE cells from hydrogen peroxide-induced damage by boosting antioxidant enzyme levels and reducing the cell death that normally follows oxidative assault.¹⁴ A separate study confirmed that SS-31 stabilized mitochondrial function in RPE cells under oxidative conditions, promoting their resilience.¹⁵

These findings led to an early-phase clinical trial in people with intermediate age-related macular degeneration. While the trial was primarily designed to assess safety rather than efficacy, it established that daily injections of elamipretide were tolerable. Most side effects were mild injection-site reactions like redness, itching, and bruising. One participant dropped out because of injection-site discomfort, and one serious adverse event (a kidney stone) occurred but was judged unrelated to the drug.¹⁶

Fighting Cellular Senescence

Cellular senescence, the state where damaged cells stop dividing but refuse to die and instead leak inflammatory signals into their surroundings, is increasingly recognized as a driver of age-related disease. Radiation exposure is one trigger, and a recent study tested whether SS-31 could prevent radiation-induced senescence in heart muscle cells. The results were striking. In irradiated cells, positive staining for a senescence marker dropped from about 67% to 38% after seven days of SS-31 treatment. The peptide also prevented increases in p16 and p21, two of the most established molecular markers of senescence, and reduced the inflammatory molecules (TNF-α, IL-6, and IL-1β) that senescent cells typically secrete. It also corrected the ratio of pro-death to pro-survival proteins on the mitochondrial membrane, suggesting it was stabilizing the cells’ decisions about whether to enter apoptosis.¹⁷

This is an emerging area, and the evidence comes from cell culture rather than whole-animal or human studies. But the connection between mitochondrial dysfunction and cellular senescence is well established, and a compound that can rescue mitochondrial function and suppress the inflammatory output of senescent cells is worth watching closely.

Human Clinical Trials and Barth Syndrome

The most advanced human evidence for elamipretide comes from trials in Barth syndrome, a rare genetic disorder in which cardiolipin metabolism is severely disrupted. People with Barth syndrome experience muscle weakness, fatigue, heart failure, and exercise intolerance, all consequences of the same mitochondrial dysfunction that SS-31 targets in animal studies. In the TAZPOWER trial, the initial randomized, placebo-controlled phase did not meet its primary endpoints. However, when participants continued on open-label treatment through 36 weeks, significant improvements emerged. Walking distance on a six-minute walk test increased by roughly 96 meters, and fatigue scores improved meaningfully.¹⁸

The long-term follow-up was arguably more compelling. Eight patients who continued treatment for 168 weeks maintained the improvements in walking distance, showed persistent reductions in fatigue, and demonstrated improving heart function over time. Cardiac volumes improved with a significant trend through the full follow-up period. The drug was well tolerated, with injection-site reactions being the main complaint.¹⁹ These results are limited by small sample size (Barth syndrome is extremely rare) and the open-label design of the extension phase, but they provide the strongest human evidence that targeting cardiolipin with SS-31 can produce lasting clinical benefit.

A larger trial in primary mitochondrial myopathy enrolled over 200 participants. While the efficacy results for that broader population are still being evaluated, the safety data were reassuring. Most adverse events were mild to moderate, with injection-site reactions being the most common. Serious adverse events were rare and not attributed to the drug. About 7% of treated participants discontinued due to side effects, compared to under 2% in the placebo group, and no deaths or hospitalizations were related to treatment.²⁰

What SS-31 Is Not

It is tempting to frame SS-31 as a universal anti-aging pill, but the evidence does not support that characterization yet. Nearly all the organ-specific benefits described above come from animal models or cell cultures, with the exception of the rare-disease clinical trials. Animal models of aging and disease are useful for establishing mechanisms, but they routinely overperform relative to what translates into humans. The history of mitochondrial medicine is full of compounds that looked transformative in rodents and then produced modest or null results in people.

SS-31 also is not a traditional antioxidant in the way most people understand the term. Oral antioxidants like vitamin C or E float through the body and scavenge free radicals wherever they encounter them, which is both imprecise and often ineffective. SS-31 does not primarily scavenge free radicals at all. Instead, it prevents excess free radicals from being produced in the first place by stabilizing the mitochondrial structures that generate them. That is a fundamentally different strategy, and it explains why SS-31 can have tissue-specific effects that generic antioxidants cannot match.

For anyone considering SS-31, the practical reality is that it currently requires injection (subcutaneous), has only been approved or under regulatory review for specific rare diseases, and is not available as an over-the-counter supplement from reputable pharmaceutical sources. Peptides sold online by research chemical suppliers have not undergone the quality controls applied to clinical-grade elamipretide, and their purity, concentration, and sterility are uncertain. The clinical safety data described above apply to pharmaceutical-grade material administered under medical supervision, and those reassurances do not automatically transfer to unregulated products.

Why Injection-Site Reactions Keep Showing Up

Across every clinical trial of elamipretide, injection-site reactions are the most frequently reported side effect, appearing in a large majority of treated patients. These reactions, including redness, itching, swelling, bruising, and occasionally small nodules, are consistently described as mild to moderate. They tend to be self-limited or manageable with local treatment.¹⁶ The pattern is so consistent that researchers treat it essentially as an expected accompaniment rather than a safety concern. The higher overall rate of adverse events in elamipretide groups compared to placebo in the mitochondrial myopathy trial was driven almost entirely by these local reactions rather than by systemic problems.²⁰ For a drug that must be injected daily, the tolerability of these reactions over months and years matters. The 168-week Barth syndrome extension data, where eight patients continued treatment without new safety signals, suggest that long-term daily injection is feasible for motivated patients, though the small numbers make broad conclusions difficult.¹⁹

1
PubMed Central. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin
2
PubMed Central. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics
3
PubMed Central. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease
4
eLife. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice
5
PubMed Central. SS31 Alleviates Pressure Overload-Induced Heart Failure Caused by Sirt3-Mediated Mitochondrial Fusion
6
PubMed Central. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice
7
PubMed Central. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice
8
PubMed Central. The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT)
9
Nephrology Dialysis Transplantation. The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy
10
PubMed Central. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
11
PubMed. SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization
12
PubMed Central. Mitochondria-targeted small peptide, SS31 ameliorates diabetes induced mitochondrial dynamics in male TallyHO/JngJ mice
13
PubMed Central. Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress
14
PubMed Central. SS-31 protect retinal pigment epithelial cells from H2O2-induced cell injury by reducing apoptosis
15
PubMed Central. Mitochondrial-Targeted Antioxidant Peptide SS31 Prevents RPE Cell Death under Oxidative Stress
16
Ophthalmology Science. Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study
17
PubMed Central. Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence
18
Genetics in Medicine. Efficacy and safety of elamipretide in Barth syndrome: a randomized, double-blind, placebo-controlled trial
19
PubMed. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
20
PubMed Central. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy